Efzofitimod for Sarcoidosis Misses Steroid Reduction

What did the efzofitimod sarcoidosis trial find?

The randomized, double-blind trial studied adults with pulmonary sarcoidosis receiving oral corticosteroids. Participants received intravenous efzofitimod at one of two doses or placebo, alongside a structured steroid taper. Its primary assessment examined changes in daily steroid requirements at week 48. The design therefore tested whether adding the investigational medicine helped patients reduce steroids beyond what supervised tapering achieved in the comparison group. [ClinicalTrials.gov trial record](https://clinicaltrials.gov/study/NCT05415137).

The main result was negative. Although complete steroid withdrawal was numerically more frequent with the higher efzofitimod dose, that comparison also did not reach statistical significance. These findings do not prove that the drug has no biological activity; they mean the trial did not establish its intended steroid-reducing benefit. The initial results were disclosed in September 2025, preceding the recent publication announcement. [Original trial results](https://investors.atyrpharma.com/node/16626).

Why are the reported symptom improvements still uncertain?

The sponsor reported favorable results with the higher dose on measures addressing lung-related quality of life, fatigue and general health. These outcomes matter because a treatment's value includes how patients feel and function. However, aTyr funded the development program, and its interpretation should be distinguished from independently established clinical benefit. [Publication announcement](https://atyrpharma.gcs-web.com/news-releases/news-release-details/atyr-pharma-announces-publication-results-phase-3-efzo-fittm).

The trial used a hierarchical statistical analysis plan: its primary comparison had to succeed before subsequent tests could support confirmatory claims under that plan. Because it failed, the reported statistical results for later comparisons are nominal. They provide signals for further research, with greater uncertainty about chance findings when several outcomes are examined. Positive secondary results cannot simply replace the unsuccessful primary result. [Trial statistical explanation](https://investors.atyrpharma.com/node/16626).

What do these results mean for sarcoidosis treatment?

Sarcoidosis can produce clusters of inflammatory cells called granulomas; lung involvement can lead to scarring and breathing difficulties. Treatment depends on symptoms, organ involvement and the risk of damage. Some patients need observation rather than medication. [NHLBI sarcoidosis overview](https://www.nhlbi.nih.gov/sites/default/files/publications/WhatIsSarcoidosis.pdf).

Prednisone remains a commonly used treatment, but prolonged exposure can contribute to high blood sugar, weight gain, hypertension and bone thinning. That burden explains the search for medicines that control disease while reducing steroid requirements. Other immune-modifying treatments, including methotrexate, may be considered according to individual circumstances. Patients should review symptoms, side effects and tapering plans with their treating clinician; the trial does not establish a steroid withdrawal schedule suitable for everyone. [NHLBI treatment guidance](https://www.nhlbi.nih.gov/health/sarcoidosis/treatment).